Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T-cell-targeted biologicals for psoriasis.

Christopher E M Griffiths1

  • 1The Dermatology Centre, Hope Hospital, University of Manchester, Manchester, UK. christopher.griffiths@man.ac.uk

Current Drug Targets. Inflammation and Allergy
|June 8, 2004
PubMed
Summary

Psoriasis is a T-cell-mediated disease. Biologic therapies targeting T cells, like alefacept and efalizumab, offer new treatment options and insights into disease mechanisms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same author

Dandruff Is a Low-Grade Inflammatory Condition Featuring Hyperproliferative Keratinocytes, Interleukin-17-Producing T Cells, and N-Acyl Ethanolamines.

Immunity, inflammation and disease·2026
Same author

Toward an understanding of neural responses to emotion in recent onset and chronic psoriasis: A feasibility brain imaging study.

JID innovations : skin science from molecules to population health·2026
Same author

Skin care without borders: A United Kingdom-Myanmar teledermatology initiative.

The Journal of investigative dermatology·2026
Same author

A survey of patients attending the Regional Dermatology Training Centre, Moshi, Tanzania, 2017-2020.

The Journal of investigative dermatology·2026
Same author

Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.

Clinical and translational science·2026

Area of Science:

  • Immunology
  • Dermatology
  • Biotechnology

Background:

  • Psoriasis is recognized as a T-cell-mediated inflammatory condition.
  • Recombinant DNA technology enables the production of biologic therapies for psoriasis.
  • Targeting T-cell function and trafficking is a rational therapeutic strategy.

Purpose of the Study:

  • To review the role of T-cell-directed biologicals in psoriasis management.
  • To discuss the utility of these agents in understanding psoriasis pathomechanisms.
  • To evaluate the potential place of T-cell-directed therapies in chronic plaque psoriasis treatment.

Main Methods:

  • Review of existing literature on T-cell-targeted therapies for psoriasis.
  • Analysis of the efficacy and application of biologic agents like alefacept and efalizumab.
  • Examination of the use of biologicals as tools to study disease mechanisms, citing anti-E-selectin as an example.

Main Results:

  • Anti-CD4 monoclonal antibodies provided early proof of concept for T-cell targeting.
  • Alefacept and efalizumab are approved U.S. Food and Drug Administration (FDA) treatments for psoriasis.
  • The non-efficacy of anti-E-selectin highlights the specificity required for effective targeting.

Conclusions:

  • T-cell-directed biologicals represent a significant advancement in psoriasis therapy.
  • These agents serve as valuable tools for elucidating psoriasis pathogenesis.
  • T-cell-directed biologicals are likely best suited for maintenance therapy in chronic plaque psoriasis due to their mechanism and safety profile for long-term use.

Related Experiment Videos